A Phase II Study of Stereotactic Body Radiation Therapy in Patients With T1N0M0 Non-Small Cell Lung Cancer (JCOG0403)
To evaluate the efficacy and safety of SBRT for T1N0M0 non-small cell lung cancer,the
following questions should be answered. Can SRT be an alternative standard treatment
modality for inoperable patients? Can SRT can be a comparable standard treatment modality
with lobectomy for operable patients? 12 Gy is the daily dose at the isocenter,and 48 Gy in
total by 4 fractions will be irradiated by stereotactic irradiation over 4 to 8 days.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
3-years overall survival
During the study conduct
No
Masahiro Hiraoka, MD, PhD
Study Chair
Kyoto Universlty Hospital
Japan: Ministry of Health, Labor and Welfare
JCOG0403
NCT00238875
July 2004
November 2011
Name | Location |
---|